BioWorld

Jan. 27, 2006

Amgen Revenues Up; Stock Drops Down On Data Delay

While Amgen Inc. recorded an 18 percent increase in revenues for 2005, the company's stock slid Thursday when it failed to release much-anticipated data for its colorectal cancer drug panitumumab. (BioWorld Today) Read More

Alexion's Soliris Phase III Outstanding' Against PNH

Altus Prices $105M IPO; Funds Earmarked For Phase III Study

Clinical Data To Test Phase III Tandem Of Vilazodone, Marker

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for Dec. 23, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 23, 2025.

Left: Anthony Fauci. Right: Transmission electron micrograph of HIV-1 virus particles

HIV research is close to a cure but far from ending the pandemic

BioWorld

Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...

Illustration of magnifying glass looking at cancer in the brain

Researchers discover how glioblastoma tumors dodge chemotherapy

BioWorld MedTech

Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...

Illustration of brain with electrical activity background

ABS-1230 controls seizures in KCNT1-driven severe epilepsy

BioWorld Science

Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...